Ketamine Effects on Learning In Eating Disorders (NCT06736769) | Clinical Trial Compass
By InvitationPhase 2
Ketamine Effects on Learning In Eating Disorders
United States20 participantsStarted 2025-06-05
Plain-language summary
This is a single site, single dose clinical trial of intravenous (IV) ketamine for medically hospitalized adolescents and young adults with anorexia nervosa or atypical anorexia nervosa. Eating disorder symptoms will be measured pre- and post-ketamine infusion. Investigators hypothesize that ketamine will increase cognitive flexibility, making medical hospitalizations less distressing by improving the ability to learn new, positive associations with food.
Who can participate
Age range16 Years – 26 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 16-26 years old
✓. Meets diagnosis of anorexia nervosa (AN) or atypical anorexia nervosa (atypical AN) per DSM-5 criteria on admission
✓. Admitted to the medical hospital for malnutrition
✓. No changes to psychiatric medications for month prior to trial enrollment
✓. Agree to use a highly effective form of contraception for at least two weeks following ketamine administration
✓. Have an outpatient primary care provider, medical provider, or behavioral health provider or psychiatrist who is actively managing or coordinating care
Exclusion criteria
✕. Lifetime history of any psychotic disorder
✕. Moderate or severe substance use disorder
✕. Pregnancy as indicated by a positive urine pregnancy test during screening, lactation, or the intention of becoming pregnant within 3 months of entry into this trial
✕. Electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS) treatment within 30 days prior to enrollment